Skip to main content
Clinical Trials/NCT05036863
NCT05036863
Completed
N/A

Feasibility Study of a Electronic Patient-Reported Outcome (ePRO) Monitoring for Patients With Multiple Myeloma and Development and Evaluation of Treatment-specific Item Lists

Medical University Innsbruck1 site in 1 country39 target enrollmentJuly 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Multiple Myeloma
Sponsor
Medical University Innsbruck
Enrollment
39
Locations
1
Primary Endpoint
Patient rated feasibility and adequacy of the item lists and symptom monitoring program
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The trial is a feasibility study of a patient-reported outcome (PRO) monitoring for patients with multiple myeloma. Patients will report weekly PROs during treatment at our outpatient unit. The trial will describe the development of treatment-specific item lists to adequately capture relevant symptoms during therapy, evaluate the feasibility of the weekly symptom monitoring, and evaluate the healthcare professional usage of the system in clinical practice.

Detailed Description

The trial is a feasibility study of a patient-reported outcome (PRO) monitoring for patients with multiple myeloma. Patients will report weekly PROs during treatment at our outpatient unit. The trial will describe the development of treatment-specific item lists to adequately capture relevant symptoms during therapy, evaluate the feasibility of the weekly symptom monitoring, and evaluate the healthcare professional usage of the system in clinical practice. The item lists will supplement an already established patient-reported outcome measure (PROM) implementation for the Austrian Myeloma Registry (AMR) at the Department of Hematology in Innsbruck. For the development of the treatment-specific item lists, a review of the literature for symptoms reported in clinical trials of the respective treatment regimens will be conducted. Then, a consensus panel of multiple stakeholders will discuss the symptoms and relevant issues for each treatment group. In an iterative process, the item lists will be developed to capture the most relevant and clinically important symptoms during active therapy to maximize clinical usage. The observational part of the trial will then test the feasibility of the electronic symptom monitoring and the treatment-specific item lists. Patients will be recruited who are already participating in a routine care patient-reported outcome monitoring. They will be given access to the web-based patient portal and asked to complete weekly assessments using the treatment-specific item lists. In larger intervals (every 6 weeks), they will also be asked to complete a larger questionnaire battery using the EORTC QLQ-C30 and the treatment-specific module (EORTC QLQ-MY20). In the patient portal, patients will also be able to review their own results and receive feedback and self-management advice. Patients will also receive reminders to remind them to use the patient portal. For healthcare professionals, the system will display the results of the PROMs and trigger alerts if patients reach thresholds for clinical importance. A clinical nurse will monitor the recently completed PROMs and contact patients who exceed the thresholds. Patients will stay on the symptom monitoring as long as they receive active treatment. They may be excluded if they move to stationary care, depending on their health status or if they want to end the monitoring. The feasibility of the weekly monitoring and items lists will be evaluated and patient feedback to the patient portal and item lists will be recorded and analysed.

Registry
clinicaltrials.gov
Start Date
July 1, 2021
End Date
June 30, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medical University Innsbruck
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Informed consent form signed
  • sufficient language proficiency in German
  • no overt cognitive impairments
  • reporting to use the internet at least once a month
  • able to log into a website using an individualized username and password (tested when patients are introduced to the patient portal)
  • patients are currently receiving active therapy for the treatment of their multiple myeloma

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Patient rated feasibility and adequacy of the item lists and symptom monitoring program

Time Frame: 6 weeks after inclusion of the patient or after the patient used the portal 3 times, whichever came first

assessed via a questionnaire, after six weeks in the program or after using the portal 3 times (whichever occurs first); ratings are provided on a 1 to 4 scale ("not at all" to "very much", higher scores are better); the evaluation questionnaire was created for the study

Assessment completion rate

Time Frame: From the inclusion of the patient until the end of the study (ie, at maximum 12 months) or until the patient withdraws, whichever came first

Calculated as the number of completed assessments divided by the number of expected assessments.

Secondary Outcomes

  • Completeness of questionnaires(From the inclusion of the patient until the end of the study (ie, at maximum 12 months) or until the patient withdraws, whichever came first)
  • Frequency of clinical alerts in the system(All alerts generated during the study period (ie, at maximum 12 months))

Study Sites (1)

Loading locations...

Similar Trials

Terminated
N/A
Electronic Patient Reported Outcomes in Measuring Health-Related Quality of Life in Patients With Stage I-IV Prostate Cancer Undergoing TreatmentProstate
NCT03197948Sidney Kimmel Cancer Center at Thomas Jefferson University20
Completed
N/A
Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing SurgeryStage I Adult Liver CancerStage I Colorectal CancerStage IA Gastric CancerStage IA Pancreatic CancerStage IB Gastric CancerStage IB Pancreatic CancerStage II Adult Liver CancerStage IIA Colorectal CancerStage IIA Gastric CancerStage IIA Pancreatic CancerStage IIB Colorectal CancerStage IIB Gastric CancerStage IIB Pancreatic CancerStage IIC Colorectal CancerStage III Pancreatic CancerStage IIIA Adult Liver CancerStage IIIA Colorectal CancerStage IIIA Gastric CancerStage IIIB Adult Liver CancerStage IIIB Colorectal CancerStage IIIB Gastric CancerStage IIIC Adult Liver CancerStage IIIC Colorectal CancerStage IIIC Gastric CancerStage IV Gastric CancerStage IVA Colorectal CancerStage IVA Liver CancerStage IVA Pancreatic CancerStage IVB Colorectal CancerStage IVB Liver CancerStage IVB Pancreatic Cancer
NCT02511821City of Hope Medical Center22
Active, Not Recruiting
N/A
Symptom Management in Patients on DialysisEnd-stage Kidney Disease
NCT05515991University Health Network, Toronto36
Recruiting
N/A
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer TreatmentCancerBreast CancerColorectal Cancer
NCT06096623UNC Lineberger Comprehensive Cancer Center240
Completed
N/A
Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer PatientsLung Cancer Stage IV
NCT03529851Regional Hospital West Jutland20